Treatment of autoimmune diseases having a pathogenic t cell state
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsAna Carrizosa ANDERSON, Davide MANGANI
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein is generally directed to methods of treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state. Disclosed are novel gene dependencies in the pathogenic immune cell state. Also, disclosed are methods for modifying immune cells characterized by the pathogenic immune cell state.
Claims20
A method of treating an autoimmune disease in a subject, comprising contacting a Th17 cell or a plurality of Th17 cells with an exogenous T cell modulating agent in an amount sufficient to:
- decrease expression of at least one pro-inflammatory Th17 transcription factor, increase expression of at least one anti-inflammatory Th17 transcription factor, or a combination thereof, and administering to the subject the Th17 cell or the plurality of Th17 cells, thereby treating the autoimmune disease.
An engineered immune cell modified to:
- a. decrease expression of one or more genes selected from Table 1A and/or one or more transcription factors selected from Table 1B;
- b. increase expression of one or more genes selected from Table 2A and/or one or more transcription factors selected from Table 2B;
- or
- c. a combination thereof.
A method of preparing an engineered immune cell for use in therapeutic compositions, comprising:
- administering one or more agents to the immune cell that can decrease expression of one or more genes selected from Table 1A and/or Table 1B, or increase expression of one or more genes selected from Table 2A and/or Table 2B, or a combination thereof.
Dependencies are inferred from the claim text.